Mantadan

Amantadine Hydrochloride, the active ingredient in Mantadan, is an antiviral presented as an oral formulation for oral use. It is employed in the prevention and treatment of influenza A infection and as an adjunct in Parkinson's disease therapy, including levodopa‑induced dyskinesia.

GNH USA supplies Mantadan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mantadan acts on viral replication and dopaminergic pathways, making it useful in specific infectious and neurological conditions.

- Influenza A infection: reduces symptom severity and shortens disease duration. - Parkinson's disease (adjunct): enhances motor control when combined with levodopa. - Levodopa‑induced dyskinesia: helps mitigate involuntary movements associated with long‑term levodopa therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Dizziness: transient light‑headedness, especially on standing. - Insomnia: difficulty initiating or maintaining sleep. - Constipation: reduced bowel motility. - Headache: mild to moderate tension‑type pain. - Anxiety: increased nervousness or restlessness.

Serious or Rare Side Effects: - Hallucinations or psychosis: severe neuropsychiatric reactions. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Cardiac arrhythmias: QT prolongation leading to irregular heartbeat. - Anaphylaxis: acute allergic response requiring emergency care. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Respiratory depression: marked reduction in breathing effort.

Mantadan should be used with careful clinical assessment and monitoring.

- Renal impairment: monitor renal function and adjust therapy as needed. - History of seizures: use cautiously, as the drug may lower seizure threshold. - Cardiac disease: evaluate risk of arrhythmias before initiating therapy. - Pregnancy: consult a physician; limited safety data are available. - Elderly patients: observe for confusion or worsening cognition. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Mantadan may interact with several medication classes; monitoring is essential.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - CNS depressants: additive sedation and respiratory depression. - QT‑prolonging drugs: increased potential for cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Anticholinergics: may diminish therapeutic effect. - Levodopa: can exacerbate dyskinesia. - Drugs cleared renally: consider dose adjustment or enhanced monitoring.